Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Value-Based Care

Latest News

New research shows that social determinants of health may significantly influence heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy. | Image credit: STOATPHOTO - stock.adobe.com.jpeg

Social Determinants of Health Linked to Worse Outcomes in Hypertrophic Cardiomyopathy

By Sabrina McCrear

January 7th 2026

Lower income and higher social deprivation were associated with increased heart failure and arrhythmia risk in patients with hypertrophic cardiomyopathy.

β-blockers were not associated with improved outcomes in patients with acute MI and preserved LVEF, according to a new meta-analysis published in JAMA Cardiology. | Image Credit: @Elena_stock.adobe.com.jpg

β-Blockers Show No Added Benefit After MI With Preserved LVEF

By Sabrina McCrear

January 7th 2026

Nimbus Therapeutics and Eli Lilly announced their partnership to develop a novel oral drug for patients with obesity and other metabolic diseases. | Image credit: ARMMY PICCA_AdobeStock.jpeg

Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug

By Sabrina McCrear

January 6th 2026

Explore AJMC’s top 5 obesity insights of 2025, covering GLP-1 therapy trends, access, costs, and strategies to improve patient care.

Top 5 Most-Read Obesity Content of 2025

By Sabrina McCrear

December 30th 2025

The key takeaways from AAD 2025 include expert insights on topical JAK safety, climate-driven skin challenges, tech innovation, and expanding equitable access in dermatology.

ICYMI: Highlights From AAD 2025

By Sabrina McCrear

December 25th 2025

More News

The Success of California's ACO Model

A blog on Health Affairs highlights California's successful ACO models that are steadily moving towards the goal of 60% of the population being cared-for by an integrated healthcare delivery system.

Read More

Experts Discuss Medicare's New Oncology Care Model

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care convened experts in health policy, from health plans, and from community oncology, to discuss OCM and other issues in oncology care during the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

Read More

The Healthcare System Future

The Healthcare System Future

Watch

Actuarial Considerations in Consumer-Directed Healthcare

Actuarial Considerations in Consumer-Directed Healthcare

Watch

High-Deductible Health Plans

High-Deductible Health Plans

Watch

Exchange Marketplaces and Narrow Networks

Exchange Marketplaces and Narrow Networks

Watch

Risk in Pharmaceutical Budgeting

Risk in Pharmaceutical Budgeting

Watch

Sustainable Growth Rate Reform

Sustainable Growth Rate Reform

Watch

Accountable Care Organizations and Risk

Accountable Care Organizations and Risk

Watch

Medicaid Expansion

Medicaid Expansion

Watch

Coordination of Patient Care in and out of ACOs

Coordination of Patient Care in and out of ACOs

Watch

Variations and Consolidations of New Healthcare Delivery Systems

Variations and Consolidations of New Healthcare Delivery Systems

Watch

Innovative Healthcare Delivery Models

Innovative Healthcare Delivery Models

Watch

Healthcare Pricing Transparency Results

Healthcare Pricing Transparency Results

Watch

Pricing Transparency Tools for the Consumer and the Provider

Pricing Transparency Tools for the Consumer and the Provider

Watch

Healthcare Pricing Transparency

Healthcare Pricing Transparency

Watch

The Evidence Supporting VBP in Health Reform

The Evidence Supporting VBP in Health Reform

Watch

Feeding Back Value-Based Performance Information to Physicians

Feeding Back Value-Based Performance Information to Physicians

Watch

Comparing State Versus Private-Employer-Run Value-Based Purchasing

Comparing State Versus Private-Employer-Run Value-Based Purchasing

Watch

Introduction: Value-Based Purchasing in Healthcare Reform

Introduction: Value-Based Purchasing in Healthcare Reform

Watch

Appropriate, Value-Based Care in Immuno-Oncology

Appropriate, Value-Based Care in Immuno-Oncology

Watch

The Cost of Care in Immuno-Oncology

The Cost of Care in Immuno-Oncology

Watch

Measuring Response With Immuno-Oncology Agents in NSCLC

Measuring Response With Immuno-Oncology Agents in NSCLC

Watch

Integrating Immunotherapy in Lung Cancer

Integrating Immunotherapy in Lung Cancer

Watch

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs

Watch

The Rationale for Initiating Therapy with an Immuno-Oncology Drug

The Rationale for Initiating Therapy with an Immuno-Oncology Drug

Watch

Anti-PD-1 Agents as Frontline Therapy

Anti-PD-1 Agents as Frontline Therapy

Watch

Anti-PD-1 Treatment Selection

Anti-PD-1 Treatment Selection

Watch

Considerations When Switching Therapy

Considerations When Switching Therapy

Watch

Determining Appropriate Duration of Treatment

Determining Appropriate Duration of Treatment

Watch

...

28 29 30 31 32 33 34 35 36

...

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2026 MJH Life Sciences
AJMC®
All rights reserved.